Spectral Medical 미래 성장

Future 기준 확인 1/6

Spectral Medical의 수익이 할 것으로 예상됩니다. 주당 순이익은 증가 연간 71.8%할 것으로 예상됩니다.

주요 정보

n/a

수익 성장률

71.8%

EPS 성장률

Biotechs 수익 성장	28.5%
매출 성장률	14.3%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	11 Nov 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

OTCPK:EDTX.F - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CAD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2025	2	N/A	N/A	N/A	1
12/31/2024	2	N/A	N/A	N/A	1
9/30/2024	2	-25	-9	-9	N/A
6/30/2024	2	-19	-9	-9	N/A
3/31/2024	2	-19	-9	-8	N/A
12/31/2023	2	-16	-11	-11	N/A
9/30/2023	2	-10	-11	-11	N/A
6/30/2023	2	-9	-10	-10	N/A
3/31/2023	2	-7	-11	-11	N/A
12/31/2022	2	-8	-10	-10	N/A
9/30/2022	2	-7	-10	-10	N/A
6/30/2022	1	-7	-10	-10	N/A
3/31/2022	2	-7	-10	-9	N/A
12/31/2021	2	-7	-9	-9	N/A
9/30/2021	2	-8	-9	-8	N/A
6/30/2021	2	-8	-9	-8	N/A
3/31/2021	2	-7	-8	-7	N/A
12/31/2020	2	-9	-1	0	N/A
9/30/2020	2	-8	-1	0	N/A
6/30/2020	2	-8	1	1	N/A
3/31/2020	3	-7	2	2	N/A
12/31/2019	3	-5	-3	-3	N/A
9/30/2019	4	-3	-2	-2	N/A
6/30/2019	4	-2	-2	-1	N/A
3/31/2019	3	-3	-2	-2	N/A
12/31/2018	4	-2	-2	-2	N/A
9/30/2018	3	-4	-3	-3	N/A
6/30/2018	3	-4	N/A	-3	N/A
3/31/2018	4	-4	N/A	-3	N/A
12/31/2017	4	-4	N/A	-4	N/A
9/30/2017	4	-4	N/A	-5	N/A
6/30/2017	4	-6	N/A	-7	N/A
3/31/2017	3	-8	N/A	-9	N/A
12/31/2016	4	-10	N/A	-11	N/A
9/30/2016	3	-11	N/A	-11	N/A
6/30/2016	3	-11	N/A	-10	N/A
3/31/2016	3	-10	N/A	-9	N/A
12/31/2015	3	-10	N/A	-9	N/A
9/30/2015	3	-10	N/A	-9	N/A
6/30/2015	3	-9	N/A	-9	N/A
3/31/2015	3	-9	N/A	-9	N/A
12/31/2014	3	-9	N/A	-10	N/A
9/30/2014	3	-11	N/A	-11	N/A
6/30/2014	3	-12	N/A	-10	N/A
3/31/2014	3	-12	N/A	-10	N/A
12/31/2013	3	-11	N/A	-9	N/A

애널리스트 미래 성장 예측

수입 대 저축률: EDTX.F 의 예상 수익 증가율이 절약률( 2.6% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: EDTX.F 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: EDTX.F 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: EDTX.F 의 수익(연간 14.3% ) US 시장( 8.9% 보다 빠르게 성장할 것으로 예상됩니다. 8.9% 연간).

고성장 수익: EDTX.F 의 수익(연간 14.3% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: EDTX.F 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Spectral Medical 미래 성장

Future 기준 확인 1/6

주요 정보

최근 미래 성장 업데이트

Recent updates

Spectral Medical Inc. Provides October Tigris Trial Update

Spectral Medical Inc. Provides September Tigris Trial Update

Spectral Medical Inc. Provides August Tigris Trial Update

Spectral Medical Inc Provides July Tigris Trial Update

Spectral Medical Inc. announced that it has received $1 million in funding

Spectral Medical Inc. announced that it expects to receive $1 million in funding

Spectral Medical Inc. Provides June Tigris Trial Update

Spectral Medical Inc. announced that it has received CAD 8.499564 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 8.499564 million in funding

Spectral Medical Inc. Provides Tigris Trial Update

Spectral Medical Provides Tigris Trial Update

Spectral Medical Inc. Announces Board Changes

Spectral Medical Inc., Annual General Meeting, Jun 07, 2024

Spectral Medical Inc. Provides Update on the Company's Tigris Trial

Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients

Spectral Medical Inc. Provides Early February Tigris Trial Update

Spectral Medical Provides January Tigris Trial Update

Spectral Medical Inc. l Enrolls Patient 82 in Its Phase 3 FDA Tigris Septic Shock Trial

Spectral Medical Inc. Provides November Tigris Trial Update

Spectral Medical Inc. Announces Executive Changes

Spectral Medical Inc. Announces Executive Changes

Spectral Medical Inc. Announces Publication of Tigris Trial Methods Paper

Spectral Medical Provides Tigris Trial Update

Spectral Medical Inc. announced that it has received CAD 6.217075 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 5 million in funding from Paradigm Capital Inc.

Spectral Medical Inc. Announces Tigris Clinical Trial Update

Spectral Medical Inc. Appoints David W. Feigal to Its Board of Directors

Spectral Medical Inc. Provides Update on Continued Favorable Tigris Clinical Trial Enrollment

Spectral Medical Inc. Provides Update on Favorable Tigris Clinical Trial Enrollment

Spectral Medical Inc. Announces Resignation of Jim Funk as Director

Spectral Medical Inc. Provides Update on Tigris Clinical Trial

Spectral Medical Inc. announced that it has received CAD 6.8364 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 8.5 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 8.5 million in funding

Spectral Medical Provides Update on Tigris Clinical Trial

US FDA Grants Spectral Medical Breakthrough Device Designation for Toraymyxin™ for the Treatment of Endotoxemic Septic Shock

Spectral Medical Inc. Elects James Funk as Director

Spectral Medical Inc. Appoints Sam Amory as Dialco, President

Spectral Medical Inc., Annual General Meeting, Jun 09, 2022

Spectral Medical Inc. Through Its Wholly-Owned Subsidiary Dialco Medical Inc. Provides Clinical Trial Update on Tigris, A Follow on Study Designed to Build on Knowledge Gained from the Earlier Euphrates Trial

Spectral Medical Inc., Annual General Meeting, Jun 03, 2021

Spectral Medical Inc. Announces Chief Executive Officer Changes, Effective April 1, 2021

Spectral Medical Inc Crescendo Communications to Provide Investor Relations Services in the United States

Spectral Medical Announces That Its Wholly-Owned Subsidiary Dialco Medical Has Been Granted FDA IDE Authorization to Conduct Trial of Dimi for Home Hemodialysis Use

Spectral Medical Inc Appoints John Kellum as Chief Medical Officer Effective March 1, 2021

Spectral Medical Inc. Announces its Wholly Owned Subsidiary Dialco Medical Receives Mdsap Certification

Spectral Medical Announces Report on Clinical Implementation of Sami Amid Covid-19 Published in the Journal of Blood Purification

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견